EveryBaby
EveryBaby is an investigational, minimal-invasive medical device that uses cervical electrical impedance to support preterm birth risk assessment. The device integrates dedicated hardware, embedded software, and clinical AI, and is being evaluated through multi-site clinical studies in Australia and additional jurisdictions.
Every baby deserves the best start
Envision a world where pregnancy and childbirth are universally celebrated as beautiful, blessed, and joyful experiences for mothers, babies, and their families.
Ridiculously accurate compared to existing methods, providing unparalleled confidence in diagnostics.
Delivers optimal results with minimal training, designed for seamless use in any healthcare setting.
Redefines diagnostic standards for preterm conditions, spanning from fetal development to neonatal care.
Out of every 10 babies born, 1 is preterm.
Every two seconds, a baby is born too soon. Tragically, every 40 seconds, one of these babies loses their life. Despite medical advancements, global preterm birth rates have remained stagnant over the past decade. Families of preterm infants face immense emotional and psychological stress, including anxiety and uncertainty about their child's health.
Sources: Comparison of Mental Health and Self-Efficacy of Mothers with Preterm and Term Infants: A Case-Control Study (2019); WHO: Born Too Soon — Decade of Action on Preterm Birth (2023).
Revolutionizing preterm birth diagnostics
EveryBaby offers a revolutionary handheld diagnostic device powered by advanced Electrical Impedance Spectroscopy (EIS) technology, delivering 21% greater diagnostic accuracy than existing methods.
With its intuitive design and efficiency, EveryBaby empowers healthcare providers worldwide to enable timely interventions and improve outcomes for mothers and babies.
Clinically validated diagnostic accuracy
- High-Risk Group (26–28 weeks): EveryBaby AUC 0.80 — vs Ultrasound and Fibronectin AUC 0.66.
- All Women Group (20–22 weeks): EveryBaby AUC 0.76 — vs Ultrasound AUC 0.72 / Fibronectin AUC 0.62.
- Enhanced accuracy with preterm birth history: spontaneous preterm birth before 37 weeks AUC 0.83; before 32 weeks AUC 0.86.
| High-Risk Group (26–28W) | AUC (95%CI) | Sensitivity | Specificity |
|---|---|---|---|
| EveryBaby | 80% | 93% | 67% |
| Transvaginal Ultrasound | 66% | 79% | 46% |
| Fetal Fibronectin | 66% | 50% | 78% |
| All Women Group (20–22W) | AUC (95%CI) | Sensitivity | Specificity |
|---|---|---|---|
| EveryBaby | 76% | 70% | 80% |
| Transvaginal Ultrasound | 72% | 62% | 75% |
| Fetal Fibronectin | 62% | 59% | 63% |
Source: Assessing the Risk of Spontaneous Premature Birth by Electrical Impedance Spectroscopy of the Cervix (449 participants).
We are preparing for our next commercial clinical trial in collaboration with PureHealth — coming soon.
Backed by peer-reviewed research
Our groundbreaking research and development efforts are backed by numerous peer-reviewed studies and publications.